Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 5:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 548 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: blood volume measurement Clear all
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

NCT03952637
View directory record Official record
Conditions
Lysosomal Diseases, Gangliosidosis, GM1
Interventions
AAV9-GLB1, Abdominal ultrasound, Rituximab, Sirolimus, Methylprednisolone, Prednisone, Audiology assessment with ABR, Bone density scan (DEXA), Electrocardiogram (EKG), Echocardiogram, Electroencephalogram (EEG) awake and extended overnight, Laboratory tests, Lumbar puncture, Brain MRI/MRS/fMRI, Neurocognitive testing, Neurology exam, PICC or other Central line placement, Skeletal survey, Skin biopsy, Speech and modified barium swallow study, Ophthalmology exam
Biological · Procedure · Drug + 3 more
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
6 Months to 12 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 6, 2026, 5:02 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Oxygen Toxicity: Mechanisms in Humans

NCT05761756
View directory record Official record
Conditions
Oxygen Toxicity, Hypercapnia, Seizures
Interventions
Sleep Deprivation, Caffeine, Methylphenidate, Carbon Dioxide
Behavioral · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 45 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 6, 2026, 5:02 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease

NCT01561053
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Albumin 5%, Albumin 20%, Immunoglobulin
Biological
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
55 Years to 85 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
22
States / cities
Sacramento, California • Denver, Colorado • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 6, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Results available

Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab

NCT01814501
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
panitumumab, irinotecan hydrochloride, fluorouracil, leucovorin calcium
Biological · Drug
Lead sponsor
John Hays
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Columbus, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 6, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Results available

Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab

NCT04401995
View directory record Official record
Conditions
Melanoma
Interventions
Vidutolimod (CMP-001), Nivolumab, [18F]F-AraG PET/CT
Drug · Biological · Other
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 6, 2026, 5:02 PM EDT
Completed No phase listed Observational

Microsampling Assays for Immunosuppressive Drugs in Children

NCT04989686
View directory record Official record
Conditions
Immunosuppression
Interventions
Microsampling
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 17 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 6, 2026, 5:02 PM EDT
Completed Phase 4 Interventional

Diuretics and Volume Overload in Early CKD

NCT05171686
View directory record Official record
Conditions
Chronic Kidney Disease, Hypertension
Interventions
Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide)
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 6, 2026, 5:02 PM EDT
Completed No phase listed Observational

Estimation of Cardiac Output in Neonatal ICU Using an Ultrasound Dilution Technique

NCT01610622
View directory record Official record
Conditions
Neonatal Intensive Care
Interventions
COstatus cardiac output measurement with isotonic saline
Device
Lead sponsor
Transonic Systems Inc.
Industry
Eligibility
Up to 1 Month
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2016 · Synced Oct 6, 2026, 5:02 PM EDT
Recruiting Phase 1Phase 2 Interventional

Delayed Tolerance Through Mixed Chimerism

NCT05900401
View directory record Official record
Conditions
Kidney Failure, Kidney Transplant; Complications, Chimera
Interventions
Bone Marrow Transplant, Peripheral Blood Stem Cell Collection, Fludarabine, Cyclophosphamide, Rituximab, Siplizumab
Other · Procedure · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 6, 2026, 5:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Measurement of Pituitary Volume and Hormonal Changes in Patients With Post-traumatic Stress Disorder

NCT00815204
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
MRI of the pituitary, DEX/CRH test
Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2015 · Synced Oct 6, 2026, 5:02 PM EDT
Completed Not applicable Interventional Results available

Physiological Changes With High-Flow Nasal Cannula

NCT03700606
View directory record Official record
Conditions
Respiratory Distress Syndrome in Premature Infant
Interventions
High flow nasal cannula, Nasal CPAP
Procedure
Lead sponsor
Sharp HealthCare
Other
Eligibility
23 Weeks to 28 Weeks
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 6, 2026, 5:02 PM EDT
Completed Not applicable Interventional Results available

A Prospective Study Evaluating the Use of Intraoperative Stroke Volume Variation Via the FloTrac Device to Guide Fluid and Vasopressor Management in Head and Neck Free Flaps

NCT02186938
View directory record Official record
Conditions
Head and Neck Cancer, Patients Requiring a Free Flap Surgery
Interventions
FloTrac
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 6, 2026, 5:02 PM EDT
Completed Phase 1 Interventional

Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease

NCT02240407
View directory record Official record
Conditions
Pompe Disease
Interventions
Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase, Rapamycin, saline, Rituxan, Diphenhydramine, Acetaminophen, Lidocaine, LMX 4 Topical Cream
Genetic · Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 6, 2026, 5:02 PM EDT
Completed Phase 3 Interventional Results available

Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML

NCT01191801
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
vosaroxin + cytarabine, placebo + cytarabine
Drug
Lead sponsor
Sunesis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
38
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 6, 2026, 5:02 PM EDT
Terminated No phase listed Observational

Observational Study of Blood Pressure Measurements and Continuous Dialysis

NCT01286506
View directory record Official record
Conditions
Kidney Failure, Respiratory Failure, Critical Illness, Shock
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Oct 6, 2026, 5:02 PM EDT
Recruiting Phase 3 Interventional

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

NCT07215910
View directory record Official record
Conditions
Astrocytoma, IDH-Mutant, Grade 3
Interventions
Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Pencil Beam Scanning, Intensity-Modulated Proton Therapy, Temozolomide, Vorasidenib, Placebo Administration, Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration
Radiation · Procedure · Drug + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
12 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2040
U.S. locations
152
States / cities
Bakersfield, California • Duarte, California • Dublin, California + 119 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 6, 2026, 5:02 PM EDT
Terminated Phase 1 Interventional

In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)

NCT02986698
View directory record Official record
Conditions
Alpha Thalassemia Major, Hemoglobinopathy; With Thalassemia, Hemoglobinopathies, Fetal Anemia, Fetal Hydrops, Alpha; Thalassemia, Thalassemia Major, Thalassemia Alpha, A-Thalassemia
Interventions
in utero hematopoietic stem cell transplantation
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Weeks to 26 Weeks
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 6, 2026, 5:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI

NCT02134314
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Failure, Delayed Graft Function, Ischemic Reperfusion Injury
Interventions
C1 Esterase Inhibitor, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 6, 2026, 5:02 PM EDT
Active, not recruiting Not applicable Interventional

Low Tidal Volume Ventilation With Hyperoxia Avoidance During Cardiopulmonary Bypass (The FOCUS Trial)

NCT04978636
View directory record Official record
Conditions
Cardiac Surgery
Interventions
Continuous low-tidal volume ventilation with using FiO2 of 0.21, Continuous low tidal volume ventilation with using FiO2 of 1.0, Apnea During CPB
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
5,502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 6, 2026, 5:02 PM EDT
Not listed Not applicable Interventional

Evaluate the SENSE Device's Ability to Monitor and Detect Intracranial Hemorrhage

NCT04642443
View directory record Official record
Conditions
Intracranial Hemorrhages, Traumatic Brain Injury
Interventions
SENSE Device
Device
Lead sponsor
Sense Diagnostics, LLC
Industry
Eligibility
22 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 6, 2026, 5:02 PM EDT
Completed Not applicable Interventional Results available

Video-based Detection of Atrial Fibrillation

NCT04267133
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Facial video of detection of cardiac disease
Diagnostic Test
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2023 · Synced Oct 6, 2026, 5:02 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of High Caffeine Content Coffee on Blood Pressure in Young Adults

NCT04060225
View directory record Official record
Conditions
High Blood Pressure
Interventions
Coffee
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 30 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 6, 2026, 5:02 PM EDT
Completed Not applicable Interventional

Adolescent Idiopathic Scoliosis (AIS) Gold Standard for Blood Loss

NCT03990376
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis
Interventions
Radioisotope I-131-labeled albumin
Other
Lead sponsor
Emory University
Other
Eligibility
10 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 6, 2026, 5:02 PM EDT
Terminated Phase 3 Interventional Results available

Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD

NCT02411084
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Begelomab, Conventional Second-line Treatment
Biological
Lead sponsor
Adienne SA
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Duarte, California • Westwood, Kansas • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Oct 6, 2026, 5:02 PM EDT